STOCK TITAN

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2021 Financial Results on November 11, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the third quarter of fiscal year 2021 will be released after the market closes on Thursday, November 11th.

Management will host a conference call at 5:00 p.m. Eastern Time on November 11th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13723897. Participants should ask for the Apyx Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at:

https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/46871/indexl.html.

A telephonic replay will be available approximately two hours after the end of the call through May 21, 2021. The replay can be accessed by dialing 877-660-6853 for U.S. callers or 201-612-7415 for international callers and using the replay access code: 13723897. The webcast will be archived on the Investor Relations section of the Company’s website.

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Westwicke on behalf of Apyx Medical Corporation

Mike Piccinino, CFA

investor.relations@apyxmedical.com

Source: Apyx Medical Corporation

Apyx Medical Corporation

NASDAQ:APYX

APYX Rankings

APYX Latest News

APYX Stock Data

53.01M
24.98M
17.92%
48.15%
2.04%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
CLEARWATER

About APYX

apyx medical corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. it operates in two segments, advanced energy and original equipment manufacturing (oem). the company develops j-plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. it markets and sells helium plasma technology under the renuvion brand name in the cosmetic surgery market and under the j-plasma brand name in the hospital surgical market. the company's renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the j-plasma system allows surgeons to operate in eliminating unintended tissue trauma. it also designs, develops, manufactures, and sells electrosurgical and oem generators and related accessories for medical device manufacturers. the company was formerly known as bovie medical corporation and changed